Pros | Among most bought funds within the category. | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | - | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 2 Years | 7 Years | ||
Fund Size | 1896 Cr | 6227 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.88% | 1.03% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 31 | 43 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.47%) Divi's Laboratories Ltd (7.76%) Glenmark Pharmaceuticals Ltd (6.93%) Lupin Ltd (6.84%) Alkem Laboratories Ltd (5.94%) | Sun Pharmaceuticals Industries Ltd (11.58%) Dr Reddy's Laboratories Ltd (9.1%) Divi's Laboratories Ltd (8.75%) Aurobindo Pharma Ltd (8.25%) Cipla Ltd (6.92%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (97.67%) Basic Materials (2.33%) | Health (97.7%) Basic Materials (1.18%) Financial Services (1.12%) | ||
Equity % | 98.97% | 97.55% | ||
Debt % | - | - | ||
P/E | 43.1 | 30.65 | ||
P/B | 6.57 | 4.17 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 3.28% | 3.76% | ||
3-Month Return | -2.01% | -1.49% | ||
6-Month Return | 8.58% | 8.54% | ||
1-Year Return | 7.49% | 5.42% | ||
3-Year Return | - | 28.1% | ||
5-Year Return | - | 21.93% |
Sharpe | - | 1.24 | ||
Alpha | - | 4.3 | ||
Beta | - | 0.95 | ||
Standard Deviation | - | 15.67 | ||
Information Ratio | - | 1.4 |
Description | HDFC Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dhruv Muchhal,Nikhil Mathur | Dharmesh Kakkad,Sharmila D’mello |